IL5 and chronic rhinosinusitis with nasal polyps: The monoclonal antibody (dupilumab) has been tested in proof-of-concept trials and scored well in comparison with anti-IL-5 (mepolizumab) and anti-IgE (omalizumab) in CRSwNP [23].